Catalyst
Slingshot members are tracking this event:
Amgen (AMGN) files supplemental Biologics License Application (sBLA) for Prolia (denosumab) in treating glucocorticoid-induced osteoporosis.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AMGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 31, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Glucocorticoid-induced Osteoporosis., Prolia, Denosumab, Sbla
